Searching On:

Disease:

Gene:

FGFR1

View:
Expand Collapse No disease selected  - General Description
Mass General Hospital Cancer Center treats patients with many cancer types. To learn more about the different cancer types that can be treated at the Cancer Center, please visit the Cancer Center website at the following page: http://www.massgeneral.org/cancer/services/
Expand Collapse FGFR1  - General Description FGFR1 is a gene that provides the code for making a protein cell surface receptor called fibroblast growth factor receptor. FGFR has 4 subtypes, FGFR 1,2,3, and 4. When certain growth factors (proteins that stimulate cell growth and division) come into contact with (bind to) this receptor, they activate a signaling system within the cell that tells it to undergo certain changes. In its normal role during development and in cells, the FGFR1 protein is believed to help the nervous system develop, and it also may help regulate the growth of long bones. Genetic alterations in the FGFR1 gene have been found in several types of cancer. These include lung, esophagus, breast, and oral cavity cancers. Cancers that have altered FGFR1 can have one of several genetic alterations. One form of genetic alteration in cancer is called gene amplification, in which the gene has been copied so there are multiple segments of DNA that code the sequence of the protein. When FGFR1 is amplified, more FGFR1 protein is produced than in normal cells. Another genetic alteration found in the FGFR1 gene in some cancers are genetic mutations, where a single change in the sequence of the DNA leads to a change in the FGFR1 protein. Both gene amplification and mutations in the DNA of FGFR1 that are found in various cancers are activating changes, changes that result in FGFR1 that cannot be regulated normally. Excessive signaling due to either amplification or genetic mutation in FGFR1 contribute to increased cells growth, division and the ability to move from the site of the primary tumor. Preclinical testing in cancer cell lines suggest that FGFR gene amplification or activation because of mutations can be an important mechanism of tumor progression that may be effectively targeted with FGFR inhibitors. This has led to the development of clinical trials evaluating FGFR inhibitors in FGFR amplified cancers, which are currently underway. Source: Genetics Home Reference FGFR1 is a gene that provides the code for making a protein cell surface receptor called fibroblast growth factor receptor. FGFR has 4 subtypes, FGFR 1,2,3, and 4. When certain growth factors (proteins that stimulate cell growth and division) come into contact with (bind to) this receptor, they activate a signaling system within the cell that tells it to undergo certain changes. In its normal role during development and in cells, the FGFR1 protein is believed to help the nervous system develop, and it also may help regulate the growth of long bones. Genetic alterations in the FGFR1 gene have been found in several types of cancer. These include lung, esophagus, breast, and oral cavity cancers. Cancers that have altered FGFR1 can have one of several genetic alterations. One form of genetic alteration in cancer is called gene amplification, in which the gene has been copied so there are multiple segments of DNA that code the sequence of the protein. When FGFR1 is amplified, more FGFR1 protein is produced than in normal cells. Another genetic alteration found in the FGFR1 gene in some cancers are genetic mutations, where a single change in the sequence of the DNA leads to a change in the FGFR1 protein. Both gene amplification and mutations in the DNA of FGFR1 that are found in various cancers are activating changes, changes that result in FGFR1 that cannot be regulated normally. Excessive signaling due to either amplification or genetic mutation in FGFR1 contribute to increased cells growth, division and the ability to move from the site of the primary tumor. Preclinical testing in cancer cell lines suggest that FGFR gene amplification or activation because of mutations can be an important mechanism of tumor progression that may be effectively targeted with FGFR inhibitors. This has led to the development of clinical trials evaluating FGFR inhibitors in FGFR amplified cancers, which are currently underway. Source: Genetics Home Reference
CLICK IMAGE FOR MORE INFORMATION
FGFR1 is a gene that provides the code for making a protein cell surface receptor called fibroblast growth factor receptor. FGFR has 4 subtypes, FGFR 1,2,3, and 4. When certain growth factors (proteins that stimulate cell growth and division) come into contact with (bind to) this receptor, they activate a signaling system within the cell that tells it to undergo certain changes. In its normal role during development and in cells, the FGFR1 protein is believed to help the nervous system develop, and it also may help regulate the growth of long bones.

Genetic alterations in the FGFR1 gene have been found in several types of cancer. These include lung, esophagus, breast, and oral cavity cancers. Cancers that have altered FGFR1 can have one of several genetic alterations. One form of genetic alteration in cancer is called gene amplification, in which the gene has been copied so there are multiple segments of DNA that code the sequence of the protein. When FGFR1 is amplified, more FGFR1 protein is produced than in normal cells. Another genetic alteration found in the FGFR1 gene in some cancers are genetic mutations, where a single change in the sequence of the DNA leads to a change in the FGFR1 protein. Both gene amplification and mutations in the DNA of FGFR1 that are found in various cancers are activating changes, changes that result in FGFR1 that cannot be regulated normally. Excessive signaling due to either amplification or genetic mutation in FGFR1 contribute to increased cells growth, division and the ability to move from the site of the primary tumor.

Preclinical testing in cancer cell lines suggest that FGFR gene amplification or activation because of mutations can be an important mechanism of tumor progression that may be effectively targeted with FGFR inhibitors. This has led to the development of clinical trials evaluating FGFR inhibitors in FGFR amplified cancers, which are currently underway.

Source: Genetics Home Reference
FGFR1 is a gene that provides the code for making a protein cell surface receptor called fibroblast growth factor receptor. FGFR has 4 subtypes, FGFR 1,2,3, and 4. When certain growth factors (proteins that stimulate cell growth and division) come into contact with (bind to) this receptor, they activate a signaling system within the cell that tells it to undergo certain changes. In its normal role during development and in cells, the FGFR1 protein is believed to help the nervous system develop, and it also may help regulate the growth of long bones.

Genetic alterations in the FGFR1 gene have been found in several types of cancer. These include lung, esophagus, breast, and oral cavity cancers. Cancers that have altered FGFR1 can have one of several genetic alterations. One form of genetic alteration in cancer is called gene amplification, in which the gene has been copied so there are multiple segments of DNA that code the sequence of the protein. When FGFR1 is amplified, more FGFR1 protein is produced than in normal cells. Another genetic alteration found in the FGFR1 gene in some cancers are genetic mutations, where a single change in the sequence of the DNA leads to a change in the FGFR1 protein. Both gene amplification and mutations in the DNA of FGFR1 that are found in various cancers are activating changes, changes that result in FGFR1 that cannot be regulated normally. Excessive signaling due to either amplification or genetic mutation in FGFR1 contribute to increased cells growth, division and the ability to move from the site of the primary tumor.

Preclinical testing in cancer cell lines suggest that FGFR gene amplification or activation because of mutations can be an important mechanism of tumor progression that may be effectively targeted with FGFR inhibitors. This has led to the development of clinical trials evaluating FGFR inhibitors in FGFR amplified cancers, which are currently underway.

Source: Genetics Home Reference
Expand Collapse No mutation selected
The mutation of a gene provides clinicians with a very detailed look at your cancer. Knowing this information could change the course of your care. To learn how you can find out more about genetic testing please visit http://www.massgeneral.org/cancer/news/faq.aspx or contact the Cancer Center.

Share with your Physican

Print information for your Physician.

Print information

Your Matched Clinical Trials

Trial Matches: (G) - Gene
Trial Status: Showing all 6 results Per Page:
Protocol # Title Location Status Match
NCT01872260 Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer MGH Open G
NCT02734615 Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers MGH Open G
NCT02684032 A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer MGH Open G
NCT02732119 Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. MGH Open G
NCT02052778 A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities MGH Open G
NCT01948297 Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations MGH Open G
MGH has many open clinical trials for other cancers not shown on the Targeted Cancer Care website. They can be found on the MassGeneral.org clinical trials search page.

Additional clinical trials may be applicable to your search criteria, but they may not be available at MGH. These clinical trials can typically be found by searching the clinicaltrials.gov website.
Trial Status: Showing all 6 results Per Page:

Share with your Physican

Print information for your Physician.

Print information